2,218 Krystal Biotech, Inc. $KRYS Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC increased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 4.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,625 shares of the company’s stock after buying an additional 2,218 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Krystal Biotech were worth $17,770,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ethic Inc. increased its position in shares of Krystal Biotech by 10.7% in the third quarter. Ethic Inc. now owns 1,335 shares of the company’s stock worth $444,000 after acquiring an additional 129 shares in the last quarter. Kornitzer Capital Management Inc. KS boosted its stake in Krystal Biotech by 24.1% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 16,293 shares of the company’s stock worth $5,418,000 after purchasing an additional 3,167 shares during the period. Pictet Asset Management Holding SA grew its position in Krystal Biotech by 10.8% during the 3rd quarter. Pictet Asset Management Holding SA now owns 119,489 shares of the company’s stock worth $39,737,000 after purchasing an additional 11,691 shares in the last quarter. AlphaCentric Advisors LLC grew its position in Krystal Biotech by 5.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 2,046 shares of the company’s stock worth $680,000 after purchasing an additional 101 shares in the last quarter. Finally, Parallel Advisors LLC grew its position in Krystal Biotech by 2.0% during the 3rd quarter. Parallel Advisors LLC now owns 1,733 shares of the company’s stock worth $576,000 after purchasing an additional 34 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on KRYS. Bank of America increased their target price on Krystal Biotech from $392.00 to $400.00 and gave the company a “buy” rating in a report on Monday, September 21st. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a report on Wednesday, September 23rd. The Goldman Sachs Group started coverage on Krystal Biotech in a research report on Thursday, September 24th. They set a “buy” rating and a $441.00 price target on the stock. TD Cowen reduced their price objective on Krystal Biotech from $403.00 to $380.00 and set a “buy” rating for the company in a research note on Tuesday, November 3rd. Finally, Chardan Capital raised Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $375.00.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the sale, the insider directly owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.10% of the company’s stock.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $305.23 on Friday. The company has a market capitalization of $9.04 billion, a price-to-earnings ratio of 41.48 and a beta of 0.56. Krystal Biotech, Inc. has a one year low of $198.02 and a one year high of $382.54. The company’s fifty day moving average price is $326.76 and its two-hundred day moving average price is $309.70.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.26. The company had revenue of $127.34 million during the quarter, compared to analysts’ expectations of $125.77 million. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. As a group, sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.74 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.